drug formulation

AcousticaBio is a venture-backed, NIH-funded preclinical biotechnology company spun out from Harvard in 2022. It helps drug developers formulate new and existing biologic products into ultra-high-concentration subcutaneous injections using its proprietary acoustophoretic fluid processing technology, enabling drugs traditionally given via lengthy intravenous infusions to be delivered through small-volume injections.

acoustophoretic technologyfluid processingsubcutaneous delivery formulation

Australis is a global biopharmaceutical company developing cancer therapies, centered on its lead compound AUS_001, a naturally derived compound discovered in honeybee propolis from Kangaroo Island. Its in-house research is based at a laboratory in Simi Valley, California, staffed by PhD scientists, with third-party research performed worldwide. AUS_001 has shown pre-clinical efficacy against 24 types of cancer and has received FDA Orphan Drug Designation for malignant gliomas and Rare Pediatric Disease Designation for pediatric-type diffuse high-grade g

clinical trial developmentGLP toxicology studiesin vitro and in vivo studiespre-clinical research

BioKier Inc. is an early-stage clinical-stage pharmaceutical company developing proprietary medical foods and drugs for diabetes and related disorders. Its lead product, BKR-017, is an oral capsule formulated to deliver L-glutamine to the colon to mimic the effects of bariatric-metabolic surgery and improve gut hormone secretion and regulation of glucose and lipids.

clinical trialspre-clinical researchtargeted colonic delivery

Inimmune is a clinical-stage biotech company founded in early 2016 by Drs. Jay Evans, David Burkhart, Helene Bazin-Lee, Kendal Ryter, and a team of 11 scientists, focused on discovering and developing disease-modifying immunotherapies and next-generation vaccines. Its pipeline includes clinical-stage Toll-like receptor agonists INI-4001 (TLR7/8 agonist) and INI-2004 (TLR4 agonist) for immuno-oncology and allergy, plus innate immune agonists and antagonists as vaccine adjuvants.

clinical translationimmunologyimmunotherapy discovery and developmentsynthetic and process chemistry

Jurata is committed to simplifying the supply chain for biologics, vaccines, and advanced therapeutics. The company creates thermostable formulations that reduce or eliminate the need for cold chain or other special handling requirements. Its technology, available in film, liquid or vialed form, simplifies manufacturing, streamlines delivery, and enables flexible administration through multiple routes without compromising efficacy. Jurata's team combines a background in drug development, formulation, and manufacturing with experience across a broad range

drug developmentmanufacturingthermostable formulation technology